Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Ruel TD, Acosta EP, Liu JP, Gray KP, George K, Montañez N, Popson S, Buchanan AM, Bartlett M, Dayton D, Anthony P, Brothers C, Vavro C, Singh R, Koech L, Vhembo T, Mmbaga BT, Pinto JA, Dobbels EFM, Archary M, Chokephaibulkit K, Ounchanum P, Deville JG, Hazra R, Townley E, Wiznia A; IMPAACT P1093 team. Ruel TD, et al. Among authors: hazra r. Lancet HIV. 2022 May;9(5):e332-e340. doi: 10.1016/S2352-3018(22)00044-3. Lancet HIV. 2022. PMID: 35489377 Free PMC article. Clinical Trial.
Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy.
Chadwick EG, Yogev R, Alvero CG, Hughes MD, Hazra R, Pinto JA, Robbins BL, Heckman BE, Palumbo PE, Capparelli EV; International Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team. Chadwick EG, et al. Among authors: hazra r. AIDS. 2011 Mar 13;25(5):643-9. doi: 10.1097/QAD.0b013e32834403f6. AIDS. 2011. PMID: 21297419 Free PMC article. Clinical Trial.
CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption.
Siberry GK, Patel K, Van Dyke RB, Hazra R, Burchett SK, Spector SA, Paul ME, Read JS, Wiznia A, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study(PHACS). Siberry GK, et al. Among authors: hazra r. J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):223-9. doi: 10.1097/QAI.0b013e318218e068. J Acquir Immune Defic Syndr. 2011. PMID: 21423022 Free PMC article.
Evaluation of viral load thresholds for predicting new World Health Organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy.
Siberry GK, Harris DR, Oliveira RH, Krauss MR, Hofer CB, Tiraboschi AA, Marques H, Succi RC, Abreu T, Della Negra M, Mofenson LM, Hazra R; NISDI PLACES Protocol. Siberry GK, et al. Among authors: hazra r. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):214-8. doi: 10.1097/QAI.0b013e31824e4da6. J Acquir Immune Defic Syndr. 2012. PMID: 22343177 Free PMC article.
Tuberculosis in HIV-infected infants, children, and adolescents in Latin America.
Krauss MR, Harris DR, Abreu T, Ferreira FG, Ruz NP, Worrell C, Hazra R; NISDI Pediatric Study Group. Krauss MR, et al. Among authors: hazra r. Braz J Infect Dis. 2015 Jan-Feb;19(1):23-9. doi: 10.1016/j.bjid.2014.08.007. Epub 2014 Oct 11. Braz J Infect Dis. 2015. PMID: 25307683 Free PMC article.
291 results